Isis
The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.
Interleukin Genetics to Provide Testing Services to Isis for Clinical Study
Interleukin will provide its genetic tests for inflammatory and metabolic diseases for a study directed at a cardiovascular disease drug in development.
NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo
Abbott's PCR/ESI-MS System Detects Rare Anaerobic Bacterium; Next-Gen Platform Under Development
Premium
NEW YORK (GenomeWeb) — A recent case study has shown the utility of combined PCR/electrospray ionization mass spectrometry (PCR/ESI-MS) for detecting a rare pathogen in a case of meningitis.
NEW YORK (GenomeWeb) – Researchers from Isis Pharmaceuticals this week published new data demonstrating the ability of a novel GalNAc conjugate to boost the potency of antisense oligonucleotides (ASOs) — including two it currently has in human trials — by as much as 10 fold in mice.
May 23, 2014
Mar 6, 2014
Jan 23, 2014
Dec 12, 2013
Oct 17, 2013
Sep 19, 2013
Sep 12, 2013
Sep 5, 2013
Aug 15, 2013
Aug 1, 2013
May 23, 2013
Apr 11, 2013
Apr 11, 2013
Apr 11, 2013
Mar 14, 2013
Feb 21, 2013